ARS Pharmaceuticals
SPRY
SPRY
74 hedge funds and large institutions have $287M invested in ARS Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 12 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
67% less capital invested
Capital invested by funds: $864M → $287M (-$577M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $136K
Holders
74
Holding in Top 10
–
Calls
–
Puts
$136K
Top Buyers
| 1 | +$9.43M | |
| 2 | +$7.85M | |
| 3 | +$6.72M | |
| 4 |
Morgan Stanley
New York
|
+$6.24M |
| 5 |
BlackRock
New York
|
+$3.48M |
Top Sellers
| 1 | -$14.3M | |
| 2 | -$13.8M | |
| 3 | -$11.5M | |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$7.39M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$7.36M |